Benzinga | Jul 30, 2021 05:55AM EDT

Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $475

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $350 to $475.